BECOME MEMBER SUPPORT
Year Cancer type Speaker
Webinar - Lung Cancer Connect - 6 March 2022
Welcome & Introduction
Lorlatinib as front-line option in ALK+ mNSCLC
Per-operative Therapy-Neoadjuvant and Adjuvant Immunotherapy
Video and slides 
CRSF Asco list of publications 
Ongoing studies 